ClinicalTrials.gg
Active, not recruitingNCT03389477Updated Apr 21, 2026Results posted

Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma

A Phase 2 interventional study of Palbociclib and Cetuximab in Head and Neck Squamous Cell Carcinoma, sponsored by Washington University School of Medicine. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Washington University School of Medicine · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Squamous Cell Carcinoma of Head and Neck by Washington University School of Medicine — 6 open to participants now, 12 under way, 1 of them phase 3. Squamous Cell Carcinoma of Head and Neck · Washington University School of Medicine.

Enrollment
20th of 23
26 · median 43
Started
2018
with 1 other
Phase 2
16 of 24
4 open now
Primary completion
2022-02
later than 0 of 11 live
Registered
10th of 24
by date

Among the 24 studies in Squamous Cell Carcinoma of Head and Neck by Washington University School of Medicine, this one is the 20th largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2018, is one of 16 in phase 2, reaches primary completion later than 0 of the 11 other live ones, and was the 10th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

6 of the 24 studies in Squamous Cell Carcinoma of Head and Neck by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Squamous Cell Carcinoma of Head and Neck by Washington University School of Medicine, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the results of treating patients with HPV-unrelated head and neck squamous cell carcinoma with neoadjuvant single-agent palbociclib, followed by chemoradiation (either cisplatin + IMRT or cetuximab + IMRT depending on patient characteristics), followed by adjuvant single-agent palbociclib.

03

Conditions studied

  • Head and Neck Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Larynx SCC, hypopharynx SCC, or oral cavity SCC. HPV-unrelated OPSCC [defined as p16INK4a negative by IHC (staining in \< 70% of cells) or HPV High Risk (Type 16 or 18) negative by ISH]. P16INK4a positive larynx SCC, hypopharynx SCC, and oral cavity SCC are eligible given the unknown effect of this on the biology of SCC of these subsites.
  • Overall Stage III, IVA, or IVB disease per AJCC version 7.0
  • defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 10 mm with CT scan, as ≥ 20 mm by chest x-ray, or ≥ 10 mm with calipers by clinical exam.
  • At least 18 years of age.
  • Normal bone marrow function as defined below:

    • ≥ 1,000/mcL
    • ≥ 100,000/mcL
    • ≥ 9.0 g/dL
  • \< 500 msec by Fridericia
  • Women of and men must agree to use adequate (hormonal or barrier method of birth control, abstinence) prior to study entry, for the duration of study participation, and for 90 days after completion of treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
  • Ability to understand and willingness to sign an IRB approved written document (or that of legally authorized representative, if applicable).

Additional Cohort 1 Eligibility Criteria: Patients enrolling to Cohort 1 must meet all of the following criteria:

  • (ECOG) performance status 0-1
  • Adequate organ function defined as:

    • Serum creatinine ≤ 1.5 x institutional (IULN) and ≥ 75 mL/min
    • ≤ 1.5 x IULN
    • and AST ≤ 2.5 x IULN

Additional Cohort 2 Eligibility Criteria: Patients enrolling to Cohort 2 must meet at least one of the following criteria:

  • ECOG performance status of 2
  • Reduced organ function defined as:

    • Creatinine clearance 30-75 mL/min
    • Bilirubin 1.5-2 x IULN
    • ALT and AST 2.5-5 x IULN

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of cutaneous, paranasal sinus, salivary, or nasopharynx SCC, or diagnosis of neck nodes with unknown primary.
  • Diagnosis of P16/HPV-ISH positive OPSCC.
  • Presence of distant disease.
  • Prior systemic therapy for current diagnosis of HNSCC.
  • A history of other ≤ 2 years previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only or low risk/curatively treated prostate, thyroid, and cervical cancers.
  • Currently receiving any other agents.
  • Treated within the last 7 days prior to Day 1 of protocol therapy with:

    • Food or drugs that are known to be STRONG inhibitors (e.g. grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole, erythromycin, clarithromycin, telithromycin, indinavir, ritonavir, nelfinavir, atazanavir, amprenavir, nefazodone, diltiazem, and delavirdine) or inducers (e.g. , progesterone, rifampin, phenobarbital, St. John's wort) [moderate CYP3A4 inhibitors/inducers are okay]
    • Drugs that are known to prolong the
    • Drugs that are proton pump inhibitors
  • A history of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib, cisplatin (for Cohort 1), or cetuximab (for Cohort 2).
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or uncontrolled electrolyte disorders that can compound the effects of a QTc-prolonging drug (e.g. hypocalcemia, hypokalemia, hypomagnesemia).
  • History of cirrhosis.
  • History of renal or liver transplant.
  • Pregnant and/or breastfeeding. Women of must have a negative serum pregnancy test within 28 days of study entry. Female patients must be surgically sterile or be , or must agree to use effective during the period of the trial and for at least 90 days after completion of treatment.
  • Known -positivity and on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with palbociclib. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy.
  • Rb (retinoblastoma) loss: mutation or homozygous deletion described on genomic sequencing report.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Cohort 1: 1: palbociclib, 2: Cisplatin & IMRT, 3: palbociclib

    * Step 1: Neoadjuvant palbociclib monotherapy (125 mg/day, Days 1-21 of a 28-day cycle for two cycles) * Step 2: Cisplatin 100 mg/m\^2 given on Days 1 and 22 with accelerated IMRT 70 Gy to be administered over 6 weeks * Step 3: Adjuvant palbociclib 125 mg/day, days 1-21 of each 28-day cycle for six cycles. Adjuvant palbociclib will begin 16 to 22 weeks following completion of cisplatin \& IMRT

    Drug: Palbociclib · Drug: Cisplatin · Radiation: Intensity-Modulated Radiation Therapy · Procedure: Tumor biopsy · Procedure: Peripheral blood draw

  • Experimental
    Cohort 2: 1: palbociclib, 2: Cetuximab & IMRT, 3: palbociclib

    * Step 1: Neoadjuvant palbociclib monotherapy (125 mg/day, Days 1-21 of a 28-day cycle for two cycles) * Step 2: Cetuximab given one week before RT and then weekly with accelerated IMRT 70 Gy to be administered over 6 weeks * Step 3: Adjuvant palbociclib 125 mg/day, days 1-21 of each 28-day cycle for six cycles. Adjuvant palbociclib will begin 16 to 22 weeks following completion of cetuximab \& IMRT

    Drug: Palbociclib · Drug: Cetuximab · Radiation: Intensity-Modulated Radiation Therapy · Procedure: Tumor biopsy · Procedure: Peripheral blood draw

Interventions

  • Palbociclib is an oral drug available as capsules (or as liquid suspension). The capsules should be taken with food

    Also known as: Ibrance, PD 0332991

  • -Cetuximab must not be administered as an IV push or bolus

    Also known as: Erbitux

  • -Patients will receive cisplatin via intravenous (IV) infusion over 60 minutes.

    Also known as: Platinol-AQ, Platinol

  • RadiationIntensity-Modulated Radiation Therapy

    -Once daily fractions Monday through Friday, with one additional fraction of RT administered on (preferably) Fridays

    Also known as: IMRT

  • ProcedureTumor biopsy

    * Tumor tissue will be collected at baseline and then after two cycles of neoadjuvant palbociclib monotherapy * If the patient has been previously enrolled in Washington University's TAP protocol (head and neck bank, HRPO #201102323), tissue that has been banked may be accessed in lieu of fresh biopsy at baseline.

  • ProcedurePeripheral blood draw

    Baseline and post-treatment

06

What researchers measure

Primary outcomes

  1. Tumor Response Rate of Newly Diagnosed p16INK4a Negative, HPV-unrelated HNSCC to Neoadjuvant Palbociclib Monotherapy

    * Tumor response rate is defined as the proportion of subjects who achieve a complete response (CR) or partial response (PR) based on RECIST criteria * CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis). * PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: 2 cycles (56 days)

Secondary outcomes

  1. Combined Local-regional Disease Relapse Risk and Distant Metastases Risk Following Completion of CRT

    * Local-regional disease relapse, a binary variable (Yes vs. No). Local-regional disease relapse rate is defined as the proportion of subjects alive who have local-regional progressed disease at 18 months following completion of CRT, stratified by cohorts. * Distant metastases, a binary variable (Yes vs. No). Distant metastases rate is defined as the proportion of subjects alive who have distant metastases at 18 months following completion of CRT, stratified by cohorts.

    Time frame: Through 18 months after completion of step 2

  2. Median Progression-free Survival (PFS) (Stratified by Cohort) of Patients Treated With the Three Step Sequence of Palbociclib Monotherapy, CRT, and Adjuvant Palbociclib Monotherapy

    -Progression-free survival (PFS), defined as the interval from the start of Step 2 (CRT) to the first documentation of disease progression or death from any cause or the end of follow-up, stratified by cohorts.

    Time frame: Through 5 years after completion of step 2

  3. Progression-free Survival (PFS) of Patients Treated With the Three Step Sequence of Palbociclib Monotherapy, CRT, and Adjuvant Palbociclib Monotherapy

    -Progression-free survival (PFS), defined as the days from the start of Step 2 (CRT) to the first documentation of disease progression or death from any cause or the end of follow-up

    Time frame: Through 2 years after completion of step 2

  4. Median Overall Survival (OS) of Patients Treated With the Three Step Sequence of Palbociclib Monotherapy, CRT, and Adjuvant Palbociclib Monotherapy

    -Overall survival (OS), defined as the days from the time of diagnosis to death from any cause or the end of follow-up

    Time frame: Through 5 years after completion of step 2

  5. Overall Survival of Patients Treated With the Three Step Sequence of Palbociclib Monotherapy, CRT, and Adjuvant Palbociclib Monotherapy

    -Overall survival (OS), defined as the days from the time of diagnosis to death from any cause or the end of follow-up

    Time frame: Through 2 years after completion of step 2

  6. Change in Genomic Alterations in Tumor Tissue

    Tumor genomic alterations at baseline and at relapse will be compared to assess for potential mechanisms of primary or secondary resistance to palbociclib.

    Time frame: At baseline and at time of disease relapse (up to 5 years)

  7. Association Between Baseline Tumor CDKN2A and CCND1 Alterations and Tumor Response to Palbociclib Given Before CRT and Relapse After CRT

    Number of participants with altered versus wild-type at baseline will be compared with response.

    Time frame: At baseline and at time of disease relapse (up to 5 years)

07

Results

Posted Mar 9, 2023

Participant flow

Step 1
Participant flow — Step 1
MilestoneCohort 1: 1: Palbociclib, 2: Cisplatin & IMRT, 3: PalbociclibCohort 2: 1: Palbociclib, 2: Cetuximab & IMRT, 3: Palbociclib
Started197
Completed187
Not completed10
Withdrew: Withdrawal by subject10
Step 2
Participant flow — Step 2
MilestoneCohort 1: 1: Palbociclib, 2: Cisplatin & IMRT, 3: PalbociclibCohort 2: 1: Palbociclib, 2: Cetuximab & IMRT, 3: Palbociclib
Started187
Completed163
Not completed24
Withdrew: Withdrawal by subject12
Withdrew: Disease progression10
Withdrew: Death01
Withdrew: Poor performance status and nutrition01
Step 3
Participant flow — Step 3
MilestoneCohort 1: 1: Palbociclib, 2: Cisplatin & IMRT, 3: PalbociclibCohort 2: 1: Palbociclib, 2: Cetuximab & IMRT, 3: Palbociclib
Started163
Completed112
Not completed51
Withdrew: Withdrawal after 3 cycles01
Withdrew: Still receiving active treatment40
Withdrew: Progressive disease after 2 cycles10

Outcome measures

PrimaryTumor Response Rate of Newly Diagnosed p16INK4a Negative, HPV-unrelated HNSCC to Neoadjuvant Palbociclib Monotherapy

* Tumor response rate is defined as the proportion of subjects who achieve a complete response (CR) or partial response (PR) based on RECIST criteria * CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis). * PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
2 cycles (56 days)
Reported as:
Count of participants · Participants
Tumor Response Rate of Newly Diagnosed p16INK4a Negative, HPV-unrelated HNSCC to Neoadjuvant Palbociclib Monotherapy
ParticipantsStep 1 Neoadjuvant Palbociclib for Cohort 1 and Cohort 2
Tumor Response Rate of Newly Diagnosed p16INK4a Negative, HPV-unrelated HNSCC to Neoadjuvant Palbociclib Monotherapy6
SecondaryCombined Local-regional Disease Relapse Risk and Distant Metastases Risk Following Completion of CRT

* Local-regional disease relapse, a binary variable (Yes vs. No). Local-regional disease relapse rate is defined as the proportion of subjects alive who have local-regional progressed disease at 18 months following completion of CRT, stratified by cohorts. * Distant metastases, a binary variable (Yes vs. No). Distant metastases rate is defined as the proportion of subjects alive who have distant metastases at 18 months following completion of CRT, stratified by cohorts.

Time frame:
Through 18 months after completion of step 2
Reported as:
Count of participants · Participants
Combined Local-regional Disease Relapse Risk and Distant Metastases Risk Following Completion of CRT
ParticipantsCohort 1: 1: Palbociclib, 2: Cisplatin & IMRT, 3: PalbociclibCohort 2: 1: Palbociclib, 2: Cetuximab & IMRT, 3: Palbociclib
Local-regional disease relapse02
Distant metastases41
Both local-regional disease relapse and distant metastases10
SecondaryMedian Progression-free Survival (PFS) (Stratified by Cohort) of Patients Treated With the Three Step Sequence of Palbociclib Monotherapy, CRT, and Adjuvant Palbociclib Monotherapy

-Progression-free survival (PFS), defined as the interval from the start of Step 2 (CRT) to the first documentation of disease progression or death from any cause or the end of follow-up, stratified by cohorts.

Time frame:
Through 5 years after completion of step 2

Results for this outcome have not been posted.

SecondaryProgression-free Survival (PFS) of Patients Treated With the Three Step Sequence of Palbociclib Monotherapy, CRT, and Adjuvant Palbociclib Monotherapy

-Progression-free survival (PFS), defined as the days from the start of Step 2 (CRT) to the first documentation of disease progression or death from any cause or the end of follow-up

Time frame:
Through 2 years after completion of step 2
Reported as:
Count of participants · Participants
Progression-free Survival (PFS) of Patients Treated With the Three Step Sequence of Palbociclib Monotherapy, CRT, and Adjuvant Palbociclib Monotherapy
ParticipantsCohort 1: 1: Palbociclib, 2: Cisplatin & IMRT, 3: PalbociclibCohort 2: 1: Palbociclib, 2: Cetuximab & IMRT, 3: Palbociclib
Progression-free Survival (PFS) of Patients Treated With the Three Step Sequence of Palbociclib Monotherapy, CRT, and Adjuvant Palbociclib Monotherapy133
SecondaryMedian Overall Survival (OS) of Patients Treated With the Three Step Sequence of Palbociclib Monotherapy, CRT, and Adjuvant Palbociclib Monotherapy

-Overall survival (OS), defined as the days from the time of diagnosis to death from any cause or the end of follow-up

Time frame:
Through 5 years after completion of step 2

Results for this outcome have not been posted.

SecondaryOverall Survival of Patients Treated With the Three Step Sequence of Palbociclib Monotherapy, CRT, and Adjuvant Palbociclib Monotherapy

-Overall survival (OS), defined as the days from the time of diagnosis to death from any cause or the end of follow-up

Time frame:
Through 2 years after completion of step 2
Reported as:
Count of participants · Participants
Overall Survival of Patients Treated With the Three Step Sequence of Palbociclib Monotherapy, CRT, and Adjuvant Palbociclib Monotherapy
ParticipantsCohort 1: 1: Palbociclib, 2: Cisplatin & IMRT, 3: PalbociclibCohort 2: 1: Palbociclib, 2: Cetuximab & IMRT, 3: Palbociclib
Overall Survival of Patients Treated With the Three Step Sequence of Palbociclib Monotherapy, CRT, and Adjuvant Palbociclib Monotherapy165
SecondaryChange in Genomic Alterations in Tumor Tissue

Tumor genomic alterations at baseline and at relapse will be compared to assess for potential mechanisms of primary or secondary resistance to palbociclib.

Time frame:
At baseline and at time of disease relapse (up to 5 years)

Results for this outcome have not been posted.

SecondaryAssociation Between Baseline Tumor CDKN2A and CCND1 Alterations and Tumor Response to Palbociclib Given Before CRT and Relapse After CRT

Number of participants with altered versus wild-type at baseline will be compared with response.

Time frame:
At baseline and at time of disease relapse (up to 5 years)

Results for this outcome have not been posted.

Adverse events

Collected over Adverse events (AEs) collected for 56 days Step 1. Step 2 Cohort 1 & Cohort 2 collected 6 weeks. Step 3 collected from start of Step 3 through 30 days following the last day of treatment. If a patient went off treatment during Step 1 or Step 2, they were collected for an additional 30 days after treatment. Median AE follow-up 376.5 days (full range 61-486 days). Median all-cause mortality follow-up 596 days (full range 61 days-1573 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Step 1 Neoadjuvant Palbociclib for Cohort 1 and Cohort 20/26 (0%)3/26 (11.5%)26/26 (100%)
Step 2 Cohort 1 (Cisplatin + IMRT)0/18 (0%)10/18 (55.6%)18/18 (100%)
Step 2 Cohort 2 (Cetuximab + IMRT)1/7 (14.3%)4/7 (57.1%)7/7 (100%)
Step 3 Adjuvant Palbociclib for Cohort 1 and Cohort 20/19 (0%)0/19 (0%)19/19 (100%)
Follow-up After Completion of Treatment8/26 (30.8%)——
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventStep 1 Neoadjuvant Palbociclib for Cohort 1 and Cohort 2Step 2 Cohort 1 (Cisplatin + IMRT)Step 2 Cohort 2 (Cetuximab + IMRT)Step 3 Adjuvant Palbociclib for Cohort 1 and Cohort 2Follow-up After Completion of Treatment
Lung infectionRespiratory, thoracic and mediastinal disorders0/261/182/7——
Laryngeal edemaRespiratory, thoracic and mediastinal disorders0/263/180/7——
DysphagiaGastrointestinal disorders0/260/181/7——
FeverGeneral disorders0/261/181/7——
Catheter related infectionInfections and infestations0/260/181/7——
HypocalcemiaMetabolism and nutrition disorders0/260/181/7——
AspirationRespiratory, thoracic and mediastinal disorders2/262/181/7——
FallInjury, poisoning and procedural complications0/262/180/7——
DeliriumPsychiatric disorders0/262/180/7——
AnemiaBlood and lymphatic system disorders1/261/180/7——
Most frequent other events
Showing 10 of 129
Most frequent other events
EventStep 1 Neoadjuvant Palbociclib for Cohort 1 and Cohort 2Step 2 Cohort 1 (Cisplatin + IMRT)Step 2 Cohort 2 (Cetuximab + IMRT)Step 3 Adjuvant Palbociclib for Cohort 1 and Cohort 2Follow-up After Completion of Treatment
White blood cell decreasedInvestigations20/2617/184/719/19—
Lymphocyte count decreasedInvestigations15/2617/186/718/19—
AnemiaBlood and lymphatic system disorders23/2617/186/715/19—
Neutrophil count decreasedInvestigations20/2612/183/717/19—
Mucositis oralGastrointestinal disorders1/2611/186/75/19—
FatigueGeneral disorders11/2613/186/711/19—
Dry mouthGastrointestinal disorders1/2615/185/713/19—
DysphagiaGastrointestinal disorders19/2615/184/710/19—
Dermatitis radiationInjury, poisoning and procedural complications0/2615/185/76/19—
Weight lossInvestigations7/2614/184/710/19—

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort 1: 1: Palbociclib, 2: Cisplatin & IMRT, 3: PalbociclibCohort 2: 1: Palbociclib, 2: Cetuximab & IMRT, 3: PalbociclibTotal
Median61 (44 to 72)66 (64 to 75)63 (44 to 75)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: 1: Palbociclib, 2: Cisplatin & IMRT, 3: PalbociclibCohort 2: 1: Palbociclib, 2: Cetuximab & IMRT, 3: PalbociclibTotal
Female437
Male15419
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: 1: Palbociclib, 2: Cisplatin & IMRT, 3: PalbociclibCohort 2: 1: Palbociclib, 2: Cetuximab & IMRT, 3: PalbociclibTotal
Hispanic or Latino000
Not Hispanic or Latino19726
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: 1: Palbociclib, 2: Cisplatin & IMRT, 3: PalbociclibCohort 2: 1: Palbociclib, 2: Cetuximab & IMRT, 3: PalbociclibTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American314
White16622
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Cohort 1: 1: Palbociclib, 2: Cisplatin & IMRT, 3: PalbociclibCohort 2: 1: Palbociclib, 2: Cetuximab & IMRT, 3: PalbociclibTotal
United States19726
08

Study locations

1 site
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Feb 2022, 45 months.

Results were first posted in Mar 2023, 1 year after primary completion.

Of 298 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's 45 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2017
First posted
Jan 3, 2018
StartActual
Apr 27, 2018
Primary completionActual
Feb 15, 2022
CompletionEst.
Apr 6, 2027
Results first posted
Mar 9, 2023
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03389477
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Jan 3, 2018
Start date
Apr 27, 2018
Primary completion
Feb 15, 2022
Completion
Apr 6, 2027 (estimated)
Results posted
Mar 9, 2023
Last update
Apr 21, 2026

Study contacts

Douglas R Adkins, M.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palbociclib

Start the discussion